Abstract
Therapeutic angiogenesis in ischemic tissues with vascular endothelial growth factors (VEGF) is a promising application of gene therapy. The transient nature of non-integrating vectors such as adenoviruses does not yield permanent therapeutic effect. On the other hand, prolonged VEGF expression by integrating vectors includes the risk of insertional mutagenesis. One way to overcome these obstacles could be combination therapy using two different transient vectors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
